• If you are wondering whether Zoetis at around US$111 is a bargain or a value trap, this article will explain what the current price might be implying about the stock.
• The stock has recently retreated, with returns of 2.3% over 7 days, 6.0% over 30 days, 11.7% year to date, and 27.6% over 1 year. This may have shifted how the market views its risk and reward trade off.
• Recent coverage has focused on Zoetis as a major animal health company, highlighting how the sector can be influenced by trends in pet ownership, livestock health spending, and regulatory developments. These themes help frame why investors might be reassessing what they are willing to pay for the stock today.
• Right now, Zoetis holds a valuation score of 5 out of 6. The sections ahead will explain what that means across different valuation methods, and then finish with a broader way to think about value that goes beyond the numbers.

Approach 1: Zoetis Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting future cash flows and then discounting them back to today using a required rate of return. It is essentially asking what all those future dollars are worth in present terms.

Zoetis currently generates trailing twelve month Free Cash Flow of about $2.21b. Analyst and extrapolated estimates used here project Free Cash Flow reaching about $3.63b by 2030, with interim annual projections such as $2.78b in 2026 and $3.10b in 2027. These later years blend analyst inputs for the first five years with Simply Wall St estimates after that, using a 2 Stage Free Cash Flow to Equity model.

When those cash flows are discounted back and combined with a terminal value, the model arrives at an estimated intrinsic value of about $211.27 per share. Against a current share price around $111, the DCF output suggests the stock is about 47.4% undervalued on this set of assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Zoetis is undervalued by 47.4%. Track this in your watchlist or portfolio, or discover 44 more high quality undervalued stocks.

Approach 2: Zoetis Price vs Earnings

For profitable companies, the P/E ratio is a straightforward way to connect what you pay per share with what the company earns per share. It helps you see how many dollars the market is willing to pay for each dollar of current earnings.

What counts as a “normal” P/E depends heavily on how investors view the company’s growth potential and risk. Higher expected growth and lower perceived risk usually justify a higher P/E, while slower growth or higher uncertainty tend to pull it down.

Zoetis currently trades on a P/E of about 17.50x. This is above the broader Pharmaceuticals industry average of about 16.69x, but below the peer average of around 22.60x. Simply Wall St’s Fair Ratio for Zoetis is 20.08x. This is its proprietary view of what the P/E could be, given factors such as earnings growth, profit margins, industry, market cap and risk profile.

The Fair Ratio is more tailored than a simple comparison with peers or the industry, because it adjusts for company specific qualities rather than relying on broad group averages. Comparing 17.50x with the Fair Ratio of 20.08x suggests the stock is trading below that tailored benchmark.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Zoetis Narrative

Earlier it was mentioned that there is an even better way to understand valuation. On Simply Wall St this comes through Narratives, which are clear stories that you and other investors build around Zoetis to connect a view about its business drivers to specific revenue, earnings and margin forecasts and then to a Fair Value that can be compared with the current share price.

On the Community page, Narratives are set up so you can quickly see how a bullish view, such as a Fair Value around US$184.42, differs from a more cautious view closer to US$127.00 or a consensus style view around US$151.00. Each of these stories is tied to explicit assumptions like revenue growth rates between about 3.8% and 7.0%, profit margins in a band of roughly 27.7% to 30.3%, and future P/E multiples between about 17.4x and 25.3x.

Because these Narratives update when new earnings, guidance, buybacks or regulatory news are added to the platform, you can see in near real time how different perspectives on Zoetis shift. You can then decide for yourself whether your own story implies a Fair Value above or below the current price and whether that means the stock looks attractive, fairly priced or expensive to you.

Do you think there's more to the story for Zoetis? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.